ETF Holdings Breakdown of BCRX

BCRX institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	161,052	USD 1,228,827
2025-09-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	21,014	USD 160,337
2025-09-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	253,546	USD 1,934,556
2025-09-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	119,045	USD 908,313
2025-09-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	119,045	USD 908,313
2025-09-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,455	USD 11,102 -0.3%
Total =		675,157	USD 5,151,448

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of “Moderate Buy” from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price […] - 2025-09-05 04:29:03

Headlands Technologies LLC Buys New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Headlands Technologies LLC bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,219 shares of the biotechnology company’s stock, valued at approximately $32,000. A number of […] - 2025-08-14 04:45:23

New Age Alpha Advisors LLC Takes $62,000 Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

New Age Alpha Advisors LLC acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,235 shares of the biotechnology company’s stock, valued at approximately $62,000. A number of other institutional […] - 2025-08-12 05:00:48

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year […] - 2025-08-11 02:28:49

XTX Topco Ltd Acquires 66,320 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

XTX Topco Ltd increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 314.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,389 shares of the biotechnology company’s stock after purchasing an additional 66,320 shares during the […] - 2025-08-06 05:57:13

Mackenzie Financial Corp Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Mackenzie Financial Corp grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 37.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 116,258 shares of the biotechnology company’s stock after purchasing an additional 31,596 shares during the period. […] - 2025-08-06 05:18:53

Universal Beteiligungs und Servicegesellschaft mbH Makes New $125,000 Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 16,704 shares of the biotechnology company’s stock, valued at approximately $125,000. Other hedge funds have also modified their […] - 2025-08-06 04:28:49

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Strong Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) shares gapped up before the market opened on Monday following a stronger than expected earnings report. The stock had previously closed at $7.95, but opened at $9.14. BioCryst Pharmaceuticals shares last traded at $8.32, with a volume of 2,333,940 shares traded. The biotechnology company reported $0.15 earnings […] - 2025-08-06 02:13:11

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Cerity Partners LLC

Cerity Partners LLC boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 203.6% in the 1st quarter, Holdings Channel reports. The firm owned 36,410 shares of the biotechnology company’s stock after purchasing an additional 24,418 shares during the period. Cerity Partners LLC’s holdings in BioCryst Pharmaceuticals were worth $273,000 at the end […] - 2025-07-28 04:46:48

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Wall Street Zen

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday. A number of other research firms have also recently commented on BCRX. Needham & Company LLC restated a “buy” rating […] - 2025-07-28 02:18:50

Y Intercept Hong Kong Ltd Buys 73,242 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Y Intercept Hong Kong Ltd grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 106.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 141,865 shares of the biotechnology company’s stock after purchasing an additional 73,242 shares during the period. Y Intercept Hong Kong Ltd’s holdings in BioCryst Pharmaceuticals were worth […] - 2025-07-25 06:52:53

Bank of America Raises BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $15.00

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its target price raised by equities research analysts at Bank of America from $13.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s target price indicates a potential upside of […] - 2025-07-03 04:38:51

Wedbush Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its price target raised by research analysts at Wedbush from $16.00 to $18.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Wedbush’s price target would indicate a potential upside of 100.00% from the company’s current price. […] - 2025-07-02 02:32:50

BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns “Outperform” Rating from Royal Bank Of Canada

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Royal Bank Of Canada in a report released on Monday,Benzinga reports. They currently have a $13.00 price objective on the biotechnology company’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 44.44% from the […] - 2025-07-02 02:32:47

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 5.2% during the first quarter, HoldingsChannel reports. The fund owned 43,496 shares of the biotechnology company’s stock after acquiring an additional 2,146 shares during the quarter. SG Americas Securities LLC’s holdings in BioCryst Pharmaceuticals were worth $326,000 […] - 2025-06-26 04:58:58

Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $16.56

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year […] - 2025-06-25 02:44:54

Millennium Management LLC Sells 634,095 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Millennium Management LLC cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 44.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 790,105 shares of the biotechnology company’s stock after selling 634,095 shares during the quarter. Millennium Management LLC’s holdings […] - 2025-05-28 04:56:50

ProShare Advisors LLC Has $511,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

ProShare Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 32.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,004 shares of the biotechnology company’s stock after purchasing an additional 16,732 shares during the period. ProShare […] - 2025-05-27 05:36:51

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Man Group plc

Man Group plc increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 46.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,954 shares of the biotechnology company’s stock after purchasing an additional 28,481 shares during the period. Man Group […] - 2025-05-26 05:01:05

Wall Street Zen Upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) to “Strong-Buy”

Wall Street Zen upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a buy rating to a strong-buy rating in a research note published on Thursday. BCRX has been the subject of several other research reports. JPMorgan Chase & Co. lifted their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the […] - 2025-05-23 04:32:52

Lazard Asset Management LLC Buys 65,420 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Lazard Asset Management LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 68.1% during the fourth quarter, Holdings Channel reports. The fund owned 161,516 shares of the biotechnology company’s stock after acquiring an additional 65,420 shares during the quarter. Lazard Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $1,214,000 as […] - 2025-05-20 06:00:50

The Manufacturers Life Insurance Company Cuts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

The Manufacturers Life Insurance Company decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 65.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 103,531 shares of the biotechnology company’s stock after selling 195,621 shares during the period. The Manufacturers Life Insurance Company’s holdings in […] - 2025-05-15 04:45:06

10,670 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,670 shares of the biotechnology company’s stock, valued at approximately $80,000. Several other institutional […] - 2025-05-14 04:26:53

Mariner LLC Grows Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Mariner LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 32.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,258 shares of the biotechnology company’s stock after purchasing an additional 3,224 shares during the quarter. […] - 2025-05-09 05:08:42

BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $17.00 Price Target at Needham & Company LLC

BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) had its price target lifted by Needham & Company LLC from $15.00 to $17.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Wedbush assumed coverage on […] - 2025-05-09 04:26:42

Tudor Investment Corp ET AL Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Tudor Investment Corp ET AL bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 99,450 shares of the biotechnology company’s stock, valued at approximately $748,000. A number of other institutional […] - 2025-05-08 06:44:51

JPMorgan Chase & Co. Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its target price lifted by JPMorgan Chase & Co. from $10.00 to $13.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 28.97% […] - 2025-05-08 05:04:48

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Earnings Beat

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report)’s stock price gapped up before the market opened on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $8.93, but opened at $9.80. BioCryst Pharmaceuticals shares last traded at $10.03, with a volume of 5,915,215 shares changing hands. The biotechnology […] - 2025-05-07 02:20:57

Investors Buy Large Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 2,675 call options on the company. This represents an increase of approximately 174% compared to the average daily volume of 975 call options. BioCryst Pharmaceuticals Price Performance Shares of BCRX stock opened at […] - 2025-05-07 02:20:55

Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $16.13

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price target among […] - 2025-05-06 02:46:52

Back to Listing

Disclaimer